Meeting
2021 ASCO Annual Meeting
Stool microbiota profiling of patients with muscle invasive bladder cancer receiving neoadjuvant pembrolizumab.
Authors
Filippo Pederzoli
Vita-Salute San Raffaele University, Milan, Italy
Filippo Pederzoli , Irene Locatelli , Michela Riba , Marco Bandini , Daniele Raggi , Laura Marandino , Elisa Alchera , Patrizia Giannatempo , Paolo Provero , Dejan Lazarevic , Roberta Lucianò , Andrea Gallina , Alberto Briganti , Francesco Montorsi , Andrea Salonia , Andrea Necchi , Massimo Alfano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4533)
DOI
10.1200/JCO.2021.39.15_suppl.4533
Abstract #
4533
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.
First Author: Heather L. McArthur
Poster
2021 Genitourinary Cancers Symposium
Concomitant antibiotics (ATBs) use and survival outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab (PURE-01 study).
First Author: Daniele Raggi
Poster
2020 Genitourinary Cancers Symposium
Secondary analysis of PURE-01: Role of FDG-PET/CT in evaluating lymph node involvement of patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant pembrolizumab and radical cystectomy (RC).
First Author: Laura Marandino
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney